Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 6/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | NPC1L1 | Q9UHC9 | 10/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5802422 | 0.88 | NPC1L1 (0.49) | NPC1L1 | |
| SCHEMBL5800911 | 0.88 | NPC1L1 (0.49) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL5800244 | 0.84 | CCR5 (0.52) | OPRM1OPRD1OPRK1OPRL1DRD3 | |
| SCHEMBL17149434 | 0.84 | ENPP2 (0.56) | ENPP2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL6619869 | 0.83 | NPC1L1 (0.48) | ENPP2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5801129 | 0.82 | ENPP2 (0.55) | ENPP2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL6629784 | 0.81 | ENPP2 (0.51) | ENPP2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5950667 | 0.81 | NPC1L1 (0.47) | ENPP2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL17140692 | 0.79 | NPC1L1 (0.58) | ENPP2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL6632197 | 0.76 | ENPP2 (0.49) | ENPP2OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241132-A1 | Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2006-10-26 | — | — | US | disclosed |
| EP-1489081-A1 | SPIRO DERIVATIVES AND ADHESION MOLECULE INHIBITORS COMPRISING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241132-A1 | Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient | VCAM1, SELL, ICAM1 | ENPP2 1493/4885OPRM1 3794/4885OPRD1 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.